Clinical Features and Comparative Treatment Outcomes of Atomoxetine and Methylphenidate in Omani Adults with ADHD
Omayma Al Kiyumi1, Tamadhir Al-Mahrouqi2, Salim Al-Huseini3
1Psychiatry Residency Training Program, Oman Medical Specialty Board, Muscat, Oman.
Objectives:
To investigate the clinical presentation and treatment outcomes in Omani adults diagnosed with attention-deficit hyperactivity disorder (ADHD), with a focus on the efficacy of atomoxetine and methylphenidate in reducing symptoms, and identify clinical predictors of treatment response.
Methods:
This prospective study enrolled Omani adults with ADHD receiving treatment at Sultan Qaboos University Hospital, Oman. Data on sociodemographic and clinical history were collected. Treatment response was quantified using the Clinical Global Impressions-Improvement (CGI-I) scale, after three months of initiating treatment. Statistical analysis used independent chi-square tests and t-tests, with a significance threshold set at p < 0.05.
Results:
Among 171 participants, 60.8% were male. The majority (80.7%) received methylphenidate, while the others (19.3%) received atomoxetine. Inattentive subtype of ADHD (66.1%) was the most common, followed by combined hyperactivity and inattention (24.0%). Most (72.5%) patients had at least one comorbidity. After three months, 83.6% of the patients showed significant improvement on the Clinical Global Impressions-Improvement scale. Response rate for methylphenidate (84.8%) was higher than for atomoxetine (78.8%). Significant predictors of treatment response were male sex (odds ratio = 2.42, 95% CI: 1.00-5.71; p = 0.044) and absence of a family history of ADHD (odds ratio = 2.93, 95% CI: 1.18-7.28; p = 0.020).
Conclusions:
Both atomoxetine and methylphenidate were effective in treating adult ADHD, but methylphenidate showed a higher response rate. Male sex and the absence of a family history of ADHD were associated with greater response to treatment. These factors may serve as clinical indicators for tailoring pharmacological treatment decisions for individual adult ADHD patients in Oman.
More Related Videos
05:48The Adventures of Fundi Intervention Based on the Cognitive and Emotional Processing in Attention Deficit Hyperactive Disorder Patients
Published on: June 12, 2020
13:09Using Brain Activation nir-HEG/Q-EEG and Execution Measures CPTs in a ADHD Assessment Protocol
Published on: April 1, 2018
Related Concept Videos
01:30Attention-Deficit/Hyperactivity Disorder
Diagnostic Criteria and Symptoms
To diagnose ADHD, symptoms must manifest before age 12 and be evident across multiple settings....
01:23Antidepressant Drugs: MAOIs and Other Agents
01:16Adrenergic Agonists: Chemistry and Structure-Activity Relationship
Aromatic ring substitutions: Substituting the aromatic ring with –OH groups at positions 3 and 4 yields catecholamines (e.g., epinephrine), which have a high affinity for adrenoceptors. Hydrogen bonding between –OH groups and receptors enhances adrenergic activity.
Separation of...
01:22Alzheimer's Disease: Treatment
01:30Adrenergic Agonists: Therapeutic Uses
Emergency and Intensive Care Unit (ICU) applications: Pressor agents increase blood pressure, heart rate, and contractility in shock and organ failure situations. Dopamine can induce vasodilation and stimulate adrenoceptors. Endogenous catecholamines are effective in treating cardiogenic shock. α2-agonists like clonidine can reverse anesthesia-induced hypertension.
Allergies and...
01:28Adrenergic Agonists: Mixed-Action Agents
Ephedrine and pseudoephedrine lack a catecholamine group, making them less susceptible to degradation by metabolic enzymes. They have increased oral bioavailability and lipophilicity, resulting in a longer duration of action. Their response is reduced by...